{
  "meta": {
    "title": "Introduction_To_Diabetes_Mellitus",
    "url": "https://brainandscalpel.vercel.app/introduction-to-diabetes-mellitus-b320557e.html",
    "scrapedAt": "2025-11-29T18:24:43.557Z"
  },
  "questions": [
    {
      "id": 19984,
      "choices": [
        {
          "id": 79897,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 mutations </span></span></span></p>"
        },
        {
          "id": 79898,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucokinase mutations </span></span></span></p>"
        },
        {
          "id": 79899,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ABCC8 activating mutations </span></span></span></p>"
        },
        {
          "id": 79900,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mtDNA mutations</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common cause of pancreatic agenesis?</span></span></p>",
      "unique_key": "Q5270252",
      "question_audio": null,
      "question_video": null,
      "map_id": 19957,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) GATA6 mutations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 is a transcription factor essential for pancreatic development. Mutations in the GATA6 gene are the most common known genetic cause of pancreatic agenesis, a condition where the pancreas fails to develop during embryogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glucokinase mutations:</span></strong><span style=\"font-size:12.0pt\"> Heterozygous mutations are associated with maturity-onset diabetes of the young (MODY) type 2, characterized by mild, stable hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Homozygous mutations are associated with severe neonatal diabetes.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ABCC8 activating mutations:</span></strong><span style=\"font-size:12.0pt\"> These mutations cause a form of neonatal diabetes that can be treated with sulfonylureas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. mtDNA mutations:</span></strong><span style=\"font-size:12.0pt\"> Mutations in mitochondrial DNA can cause a rare form of diabetes associated with deafness, but not typically pancreatic agenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 mutations are the most common cause of pancreatic agenesis.</span></span></span></p>",
      "correct_choice_id": 79897,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53899,
      "choices": [
        {
          "id": 215069,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alzheimer&rsquo;s disease </span></span></span></p>"
        },
        {
          "id": 215070,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gout </span></span></span></p>"
        },
        {
          "id": 215071,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-alcoholic fatty liver disease </span></span></span></p>"
        },
        {
          "id": 215072,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polycystic ovarian syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with metabolic syndrome are at higher risk for all of the following EXCEPT:</span></span></span></p>",
      "unique_key": "Q1303613",
      "question_audio": null,
      "question_video": null,
      "map_id": 25494,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Alzheimer&#39;s disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While there is some evidence suggesting a potential link between metabolic syndrome and an increased risk of Alzheimer&#39;s disease, the association is not as strong or well-established as the link between metabolic syndrome and the other options listed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Gout:</span></strong><span style=\"font-size:12.0pt\"> The metabolic syndrome is associated with increased uric acid levels, a key risk factor for gout.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nonalcoholic fatty liver disease (NAFLD):</span></strong><span style=\"font-size:12.0pt\"> Insulin resistance, a central feature of metabolic syndrome, is strongly linked to the development of NAFLD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Polycystic ovarian syndrome (PCOS):</span></strong><span style=\"font-size:12.0pt\"> Insulin resistance is also a key factor in the development of PCOS, and metabolic syndrome is frequently seen in women with PCOS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metabolic syndrome is linked with gout, non-alcoholic fatty liver disease, and polycystic ovarian syndrome but not strongly with Alzheimer&#39;s disease.</span></span></span></p>",
      "correct_choice_id": 215069,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53909,
      "choices": [
        {
          "id": 215105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pharmacotherapy </span></span></span></p>"
        },
        {
          "id": 215106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bariatric surgery</span></span></span></p>"
        },
        {
          "id": 215107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diet, exercise, and behavioral therapy </span></span></span></p>"
        },
        {
          "id": 215108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No intervention needed</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with a BMI of 31 kg/m&sup2; and no obesity-related comorbidities is seeking advice on weight management. What is the most appropriate initial intervention for this patient?</span></span></p>",
      "unique_key": "Q5070152",
      "question_audio": null,
      "question_video": null,
      "map_id": 25503,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Diet, exercise, and behavioral therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A BMI of 31 kg/m&sup2; falls into the obesity class I category. The most appropriate initial intervention for individuals with obesity class I and no comorbidities is lifestyle modification, which includes diet, exercise, and behavioral therapy. These interventions aim to create a calorie deficit and promote sustainable weight loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pharmacotherapy:</span></strong><span style=\"font-size:12.0pt\"> While pharmacotherapy can be an adjunct to lifestyle modification for weight loss, it is not the first-line treatment for patients with obesity class I without comorbidities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bariatric surgery:</span></strong><span style=\"font-size:12.0pt\"> Bariatric surgery is reserved for patients with severe obesity (BMI &ge; 40 kg/m&sup2;) or those with BMI &ge; 35 kg/m&sup2; and significant comorbidities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No intervention needed:</span></strong><span style=\"font-size:12.0pt\"> Although the patient does not have any current comorbidities, a BMI of 31 kg/m&sup2; puts her at risk for developing obesity-related health problems in the future. Therefore, intervention is recommended to prevent these complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-104442.png\" style=\"height:269px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial intervention for patients with class I obesity without comorbidities should be diet, exercise, and behavioral therapy.</span></span></span></p>",
      "correct_choice_id": 215107,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19961,
      "choices": [
        {
          "id": 79805,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLP1 and GIP reduce insulin secretion. </span></span></span></p>"
        },
        {
          "id": 79806,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Portal to peripheral insulin ratio is 1:1 </span></span></span></p>"
        },
        {
          "id": 79807,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose &lt; 70 mg/dL shuts off insulin secretion. </span></span></span></p>"
        },
        {
          "id": 79808,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin release from beta cells is glucose independent.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding insulin is correct?</span></span></p>",
      "unique_key": "Q1185668",
      "question_audio": null,
      "question_video": null,
      "map_id": 19935,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Glucose &lt; 70 mg/dL shuts off insulin secretion.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin secretion is tightly regulated by blood glucose levels. When blood glucose levels fall below a threshold (typically around 70 mg/dL), insulin secretion is suppressed to prevent hypoglycemia. This is a crucial mechanism for maintaining glucose homeostasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. GLP1 and GIP reduce insulin secretion:&nbsp;</span></strong><span style=\"font-size:12.0pt\">GLP1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide) are incretin hormones that actually <em>increase</em> insulin secretion in response to oral glucose intake.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Portal to peripheral insulin ratio is 1:1:</span></strong><span style=\"font-size:12.0pt\"> The portal to peripheral insulin ratio is approximately 2:1, as a significant portion (50%) of insulin is cleared by the liver in the first pass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulin release from beta cells is glucose independent:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect. Glucose is the primary stimulator of insulin secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose levels below 70 mg/dL shut off insulin secretion to prevent hypoglycemia.</span></span></span></p>",
      "correct_choice_id": 79807,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19980,
      "choices": [
        {
          "id": 79881,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79882,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79883,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus </span></span></span></p>"
        },
        {
          "id": 79884,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old patient came with the following reports. What is the likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-093727.png\" style=\"height:212px; width:500px\" /></span></span></p>",
      "unique_key": "Q3630101",
      "question_audio": null,
      "question_video": null,
      "map_id": 19953,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Diabetes Mellitus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s blood glucose values meet the criteria for diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FBS (Fasting Blood Sugar):</span></strong><span style=\"font-size:12.0pt\"> 138 mg/dL is above the normal range (&lt;100 mg/dL) and within the range for diabetes (&ge;126 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2-hour PG (2-hour Postprandial Glucose):</span></strong><span style=\"font-size:12.0pt\"> 260 mg/dL is well above the normal range (&lt;140 mg/dL) and the range for impaired glucose tolerance (140-199 mg/dL), indicating diabetes (&ge;200 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HbA1c (Glycated Hemoglobin):</span></strong><span style=\"font-size:12.0pt\"> 7.9% is above the normal range (&lt;5.7%) and the range for prediabetes (5.7-6.4%), confirming the diagnosis of diabetes (&ge;6.5%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> All values should be within the normal range for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Impaired glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> The 2-hour PG value is too high for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. None of the above:</span></strong><span style=\"font-size:12.0pt\"> The correct answer is listed in the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus is diagnosed with fasting blood sugar &ge;126 mg/dL, 2-hour postprandial glucose &ge;200 mg/dL, or HbA1c &ge;6.5%.</span></span></span></p>",
      "correct_choice_id": 79883,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19989,
      "choices": [
        {
          "id": 79917,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Preprandial 80-130 mg/dL </span></span></span></p>"
        },
        {
          "id": 79918,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Postprandial &lt; 180 mg/dL </span></span></span></p>"
        },
        {
          "id": 79919,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1C &lt; 7% </span></span></span></p>"
        },
        {
          "id": 79920,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Goals should be more stringent in older adults</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect regarding glycemic targets in non-pregnant diabetics?</span></span></p>",
      "unique_key": "Q9411414",
      "question_audio": null,
      "question_video": null,
      "map_id": 19962,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Goals should be more stringent in older adults</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The American Diabetes Association (ADA) recommends that glycemic targets should be individualized for each patient, taking into account their age, overall health, and risk of hypoglycemia. While a HbA1c goal of &lt;7.0% is appropriate for many non-pregnant adults with diabetes, <strong>less stringent goals</strong> may be appropriate for older adults, especially those with a history of severe hypoglycemia, limited life expectancy, or advanced microvascular or macrovascular complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Preprandial 80-130 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is the correct target range for preprandial capillary plasma glucose according to the ADA guidelines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Postprandial &lt; 180 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is the correct target range for peak postprandial capillary plasma glucose according to the ADA guidelines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. HbA1C &lt; 7%:</span></strong><span style=\"font-size:12.0pt\"> This is the general target for HbA1c in most non-pregnant adults with diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-095420.png\" style=\"height:507px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic targets in older adults should be less stringent due to increased risk of hypoglycemia.</span></span></span></p>",
      "correct_choice_id": 79920,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53901,
      "choices": [
        {
          "id": 215077,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leptin </span></span></span></p>"
        },
        {
          "id": 215078,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin </span></span></span></p>"
        },
        {
          "id": 215079,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin</span></span></span></p>"
        },
        {
          "id": 215080,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TNF-&alpha;</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is reduced in obese patients?</span></span></span></p>",
      "unique_key": "Q3879598",
      "question_audio": null,
      "question_video": null,
      "map_id": 25496,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Adiponectin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin is a hormone produced by adipocytes (fat cells) that plays a role in regulating glucose and lipid metabolism. It has anti-inflammatory and insulin-sensitizing effects. In obese patients, adiponectin levels are often <strong>reduced</strong>, contributing to insulin resistance and the development of metabolic syndrome. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Leptin:</span></strong><span style=\"font-size:12.0pt\"> Leptin levels are typically elevated in obese patients, but its signaling is often impaired (leptin resistance). Elevated leptin is associated with endothelial damage resulting in CV risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insulin:</span></strong><span style=\"font-size:12.0pt\"> Insulin levels are often elevated in obese patients due to insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TNF-&alpha;:</span></strong><span style=\"font-size:12.0pt\"> TNF-&alpha; (and IL-6) is increased in obesity, contributing to the chronic low-grade inflammation, which can cause endothelial injury and increase CV risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin levels are reduced in obese patients, contributing to insulin resistance and metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Adipokines in Obesity:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Increased:</span></u><span style=\"font-size:12.0pt\"> Leptin, Insulin, Resistin, Proinflammatory cytokines (IL6/ TNF &alpha;)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Decreased<em>:</em></span></u><span style=\"font-size:12.0pt\"> Adiponectin, Ghrelin</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 215078,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19963,
      "choices": [
        {
          "id": 79813,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibodies </span></span></span></p>"
        },
        {
          "id": 79814,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD4 T cells </span></span></span></p>"
        },
        {
          "id": 79815,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD8 T cells </span></span></span></p>"
        },
        {
          "id": 79816,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inflammatory cytokines</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In type 1 diabetes, &beta; cell destruction is primarily mediated by:</span></span></span></p>",
      "unique_key": "Q6711529",
      "question_audio": null,
      "question_video": null,
      "map_id": 19937,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) CD8 T cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all of the listed options play a role in the pathogenesis of type 1 diabetes, the direct destruction of beta cells is primarily mediated by cytotoxic CD8+ T cells. These cells recognize specific antigens presented on the surface of beta cells and induce apoptosis, leading to their destruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antibodies:</span></strong><span style=\"font-size:12.0pt\"> Autoantibodies against beta cell antigens are present in type 1 diabetes and serve as markers of the disease, but they do not directly cause beta cell death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CD4 T cells:</span></strong><span style=\"font-size:12.0pt\"> CD4 T cells play a role in activating and coordinating the immune response, but they are not the primary mediators of beta cell destruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inflammatory cytokines:</span></strong><span style=\"font-size:12.0pt\"> Cytokines released by immune cells contribute to the inflammatory environment and can indirectly damage beta cells, but the direct killing is primarily mediated by CD8+ T cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD8 T cells are the primary mediators of &beta; cell destruction in type 1 diabetes.</span></span></span></p>",
      "correct_choice_id": 79815,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19988,
      "choices": [
        {
          "id": 79913,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CV (Coefficient of Variation) is an equivalent of HbA1c </span></span></span></p>"
        },
        {
          "id": 79914,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CGM measures interstitial glucose </span></span></span></p>"
        },
        {
          "id": 79915,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low rates of hypo and hyperglycemia if used with insulin infusion device </span></span></span></p>"
        },
        {
          "id": 79916,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CGM can detect hypoglycemic unawareness</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding Continuous Glucose Monitoring (CGM) in diabetes?</span></span></p>",
      "unique_key": "Q8316543",
      "question_audio": null,
      "question_video": null,
      "map_id": 19961,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CV (Coefficient of Variation) is an equivalent of HbA1c</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CV and HbA1c are not equivalent:</span></strong><span style=\"font-size:12.0pt\"> The coefficient of variation (CV) measures glucose variability, or how much glucose levels fluctuate. GMI (Glucose Management Indicator) is a vague equivalent of HbA1C since both indicate MBG (Mean Blood Glucose).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CGM measures interstitial glucose:</span></strong><span style=\"font-size:12.0pt\"> CGM does not directly measure blood glucose. It measures glucose levels in the interstitial fluid, which closely reflects blood glucose but with a slight time lag.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Low rates of hypo and hyperglycemia if used with insulin infusion device:</span></strong><span style=\"font-size:12.0pt\"> CGM, especially when integrated with insulin pumps (forming a hybrid closed-loop system), can significantly reduce the risk of hypoglycemia and hyperglycemia by providing real-time data and automated insulin adjustments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CGM can detect hypoglycemic unawareness:</span></strong><span style=\"font-size:12.0pt\"> CGM can alert patients to impending hypoglycemia, even if they are not experiencing typical symptoms, thus helping to prevent severe hypoglycemic events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coefficient of Variation (CV) measures glucose variability and is not equivalent to HbA1c.</span></span></span></p>",
      "correct_choice_id": 79913,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53898,
      "choices": [
        {
          "id": 215065,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HDL cholesterol level of 58 mg/dL </span></span></span></p>"
        },
        {
          "id": 215066,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Triglyceride level of 160 mg/dL</span></span></span></p>"
        },
        {
          "id": 215067,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Taking a statin for hypercholesterolemia </span></span></span></p>"
        },
        {
          "id": 215068,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BMI of 28 kg/m&sup2;</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman from Chennai presents with a waist circumference of 92 cm, a blood pressure of 120/80 mmHg, and a fasting blood glucose of 110 mg/dL. Which of the following additional findings would be needed to diagnose metabolic syndrome?</span></span></p>",
      "unique_key": "Q6748120",
      "question_audio": null,
      "question_video": null,
      "map_id": 25493,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Triglyceride level of 160 mg/dL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to the harmonizing definition of metabolic syndrome, at least 3 of the following five criteria are needed for diagnosis:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Abdominal obesity:</span></strong><span style=\"font-size:12.0pt\"> Waist circumference &gt;90cm for South Asian women (which the patient meets with 92 cm)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Triglycerides:</span></strong><span style=\"font-size:12.0pt\"> &ge;150 mg/dL (1.7 mmol/L) (which the patient would meet with 160 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HDL cholesterol:</span></strong><span style=\"font-size:12.0pt\"> &lt;50 mg/dL (1.29 mmol/L) in women</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Blood pressure:</span></strong><span style=\"font-size:12.0pt\"> &ge;130/85 mmHg or on antihypertensive medication</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Fasting glucose:</span></strong><span style=\"font-size:12.0pt\"> &ge;100 mg/dL (5.6 mmol/L) or diagnosed type 2 diabetes (which the patient meets with 110 mg/dL)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient already meets the criteria for abdominal obesity and impaired fasting glucose. With the additional finding of elevated triglycerides (&ge;150 mg/dL), she would meet three criteria and thus be diagnosed with metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-100019.png\" style=\"height:653px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HDL cholesterol level of 58 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is within normal limits (&gt;50 mg/dL) and does not contribute to the diagnosis of metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Taking a statin for hypercholesterolemia:</span></strong><span style=\"font-size:12.0pt\"> This is a treatment for high cholesterol but is not a diagnostic criterion for metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. BMI of 28 kg/m&sup2;:</span></strong><span style=\"font-size:12.0pt\"> This is considered overweight but not obese, and while it can be associated with metabolic syndrome, it is not a direct diagnostic criterion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metabolic syndrome diagnosis requires at least three criteria, including central obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, or high fasting glucose.</span></span></span></p>",
      "correct_choice_id": 215066,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19955,
      "choices": [
        {
          "id": 79781,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketogenic diet </span></span></span></p>"
        },
        {
          "id": 79782,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisolone </span></span></span></p>"
        },
        {
          "id": 79783,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valproate d</span></span></span></p>"
        },
        {
          "id": 79784,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lamotrigine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A neonate presents with seizures, microcephaly, and developmental delay. Brain imaging reveals abnormalities in the white matter. Genetic testing confirms a mutation in the SLC2A1 gene. What is the treatment of choice?</span></span></p>",
      "unique_key": "Q5683558",
      "question_audio": null,
      "question_video": null,
      "map_id": 19929,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Ketogenic diet</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The mutation in the SLC2A1 gene indicates GLUT1 deficiency syndrome, a rare metabolic disorder characterized by impaired glucose transport across the blood-brain barrier. This leads to neuroglycopenia (low glucose in the brain), causing seizures, developmental delay, and movement disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ketogenic diet is the treatment of choice for GLUT1 deficiency syndrome, bypassing the need for glucose transport via GLUT1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prednisolone:</span></strong><span style=\"font-size:12.0pt\"> This is a corticosteroid used to treat inflammation and autoimmune conditions. It is not effective in GLUT1 deficiency syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Valproate&nbsp;</span></strong><span style=\"font-size:12.0pt\">and </span><strong><span style=\"font-size:12.0pt\">Option D. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> These are anti-seizure medications that are generally ineffective in controlling seizures associated with GLUT1 deficiency syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-091146.png\" style=\"height:416px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLUT1 deficiency syndrome, caused by SLC2A1 gene mutation, is best treated with a ketogenic diet to bypass glucose transport issues.</span></span></span></p>",
      "correct_choice_id": 79781,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53906,
      "choices": [
        {
          "id": 215093,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
        },
        {
          "id": 215094,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide </span></span></span></p>"
        },
        {
          "id": 215095,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orlistat </span></span></span></p>"
        },
        {
          "id": 215096,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phentermine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is not approved for general obesity?</span></span></p>",
      "unique_key": "Q7851437",
      "question_audio": null,
      "question_video": null,
      "map_id": 25500,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Setmelanotide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide is not approved for general obesity. It is specifically approved for the treatment of obesity in patients with certain rare genetic conditions, such as proopiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> This GLP-1 receptor agonist is approved for chronic weight management in adults with general obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Orlistat:</span></strong><span style=\"font-size:12.0pt\"> This lipase inhibitor is approved for weight loss in adults and adolescents with obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Phentermine:</span></strong><span style=\"font-size:12.0pt\"> This appetite suppressant is approved for short-term use in adults with obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide is not approved for general obesity but for specific genetic conditions like POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome.</span></span></span></p>",
      "correct_choice_id": 215094,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53904,
      "choices": [
        {
          "id": 215085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common mechanism of imprinting center mutations </span></span></span></p>"
        },
        {
          "id": 215086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of SNRPN gene </span></span></span></p>"
        },
        {
          "id": 215087,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inherited in autosomal dominant pattern </span></span></span></p>"
        },
        {
          "id": 215088,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced Ghrelin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding Prader Willi Syndrome (PWS)?</span></span></p>",
      "unique_key": "Q5102124",
      "question_audio": null,
      "question_video": null,
      "map_id": 25498,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Loss of SNRPN gene</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi Syndrome (PWS) is caused by the lack of expression of paternal genes in the 15q11-q13 region on chromosome 15. The SNRPN gene is a key imprinted gene in this region and its loss of expression contributes to the features of PWS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common mechanism of imprinting center mutations:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While imprinting center mutations can cause PWS, the <em><u>most common mechanism is a deletion</u></em> of the paternal 15q11-q13 region (about 70% of cases). 25% cases are due to maternal uniparental disomy and &lt; 1% cases are due to imprinting center mutations. <em><u>FISH is the 1<sup>st</sup> line diagnostic test</u></em> in PWS. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inherited in autosomal dominant pattern:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Most cases of PWS are <em><u>sporadic</u></em> and do not show Mendelian inheritance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reduced Ghrelin:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><em><u>Ghrelin levels are actually elevated</u></em> in individuals with PWS, contributing to their hyperphagia and obesity. Patients with PWS also show <em><u>reduced BDNF</u></em> expression, contributing to hyperphagia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi syndrome is primarily caused by the loss of the SNRPN gene, leading to hyperphagia and obesity.</span></span></span></p>",
      "correct_choice_id": 215086,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19982,
      "choices": [
        {
          "id": 79889,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c </span></span></span></p>"
        },
        {
          "id": 79890,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral glucose tolerance test </span></span></span></p>"
        },
        {
          "id": 79891,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Plasma C-peptide level</span></span></span></p>"
        },
        {
          "id": 79892,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Random plasma glucose level</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 37-year-old obese woman presents to the clinic for a routine health evaluation. She frequently feels thirsty and wakes up at night to urinate. Which of the following studies is the most appropriate first test in evaluating this patient for diabetes mellitus?</span></span></p>",
      "unique_key": "Q8462291",
      "question_audio": null,
      "question_video": null,
      "map_id": 19955,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Random plasma glucose level</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms of thirst, polyuria, and recurrent yeast infections raise strong suspicion for diabetes mellitus. Given these symptoms, a random plasma glucose test is the most appropriate initial test. A random plasma glucose level of &gt;200 mg/dL, along with her symptoms, would be diagnostic of diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hemoglobin A1c:</span></strong><span style=\"font-size:12.0pt\"> While HbA1c is a valuable test for assessing long-term glycemic control, it is not the initial test of choice in a symptomatic patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oral glucose tolerance test (OGTT):</span></strong><span style=\"font-size:12.0pt\"> OGTT is another diagnostic test for diabetes, but it is more time-consuming and not necessary if the random plasma glucose is diagnostic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Plasma C-peptide level:</span></strong><span style=\"font-size:12.0pt\"> C-peptide is a marker of endogenous insulin production and is useful in distinguishing between type 1 and type 2 diabetes or evaluating hypoglycemia. It is not the first-line test for diagnosing diabetes in a symptomatic patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Random plasma glucose level is the most appropriate first test for evaluating a symptomatic patient for diabetes mellitus.</span></span></span></p>",
      "correct_choice_id": 79892,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19959,
      "choices": [
        {
          "id": 79797,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of lipolysis </span></span></span></p>"
        },
        {
          "id": 79798,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suppression of ketosis </span></span></span></p>"
        },
        {
          "id": 79799,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased glucose and potassium uptake by cells </span></span></span></p>"
        },
        {
          "id": 79800,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Induces vasoconstriction</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT insulin-mediated?</span></span></p>",
      "unique_key": "Q8316450",
      "question_audio": null,
      "question_video": null,
      "map_id": 19933,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Induces vasoconstriction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin does not directly cause vasoconstriction. In fact, it has some vasodilatory effects through the production of nitric oxide. Vasoconstriction is typically mediated by other hormones like angiotensin II and catecholamines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Inhibition of lipolysis:</span></strong><span style=\"font-size:12.0pt\"> Insulin suppresses the breakdown of stored fats, preventing the release of free fatty acids into the bloodstream.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Suppression of ketosis:</span></strong><span style=\"font-size:12.0pt\"> By promoting glucose utilization, insulin reduces the need for ketone body production, which occurs when the body relies on fats for energy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased glucose and potassium uptake by cells:</span></strong><span style=\"font-size:12.0pt\"> Insulin stimulates glucose transporters (GLUT4) to move to the cell surface, facilitating glucose uptake. It also activates the sodium-potassium pump, promoting potassium uptake.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary of insulin action:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Increased:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Glycogenesis, protein synthesis, lipogenesis, NO production (vasodilation).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Decreased:</span></strong><span style=\"font-size:12.0pt\"> Glycogenolysis, lipolysis, ketosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pathway:</span></strong><span style=\"font-size:12.0pt\"> RTK </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span style=\"font-size:12.0pt\"> IRS </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span style=\"font-size:12.0pt\"> Pi3k/Akt </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span style=\"font-size:12.0pt\"> &uarr; GLUT-4 translocation + &darr; GSK3 (activates glycogen synthase)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin inhibits lipolysis, suppresses ketosis, and increases glucose and potassium uptake but does not induce vasoconstriction.</span></span></span></p>",
      "correct_choice_id": 79800,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19975,
      "choices": [
        {
          "id": 79861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 0 </span></span></span></p>"
        },
        {
          "id": 79862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 1 </span></span></span></p>"
        },
        {
          "id": 79863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 2 </span></span></span></p>"
        },
        {
          "id": 79864,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 3</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child comes for a routine check-up, and you notice that the child is positive for GAD and ZnT8 antibodies. The blood sugar levels are normal. What stage of type 1 diabetes is the patient in?</span></span></p>",
      "unique_key": "Q4571935",
      "question_audio": null,
      "question_video": null,
      "map_id": 19949,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Stage 1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of two or more autoantibodies (in this case, GAD and ZnT8), even with normal blood sugar levels, indicates Stage 1 of type 1 diabetes. In this stage, the immune system has begun attacking the insulin-producing beta cells in the pancreas, but there are no symptoms and blood sugar levels remain normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Stage 0:</span></strong><span style=\"font-size:12.0pt\"> This stage represents a pre-clinical period where no autoantibodies have been detected. Patients may have genetic predisposition alone. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Stage 2:&nbsp;</span></strong><span style=\"font-size:12.0pt\">In this stage, individuals have multiple autoantibodies and dysglycemia (abnormal blood sugar levels). <em><u>Teplizumab</u></em> (anti CD3 mAb) has been approved for &ge; 8 years + stage 2 type 1 Diabetes (for delaying the progression to stage 3).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Stage 3:</span></strong><span style=\"font-size:12.0pt\"> This is the stage of overt diabetes, where the beta cells are destroyed and insulin production is insufficient, leading to hyperglycemia and symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-092103.png\" style=\"height:414px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 1 type 1 diabetes is characterized by the presence of multiple autoantibodies with normal blood glucose levels.</span></span></span></p>",
      "correct_choice_id": 79862,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19976,
      "choices": [
        {
          "id": 79865,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced Insulin receptor levels </span></span></span></p>"
        },
        {
          "id": 79866,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced Tyrosine kinase activity </span></span></span></p>"
        },
        {
          "id": 79867,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased insulin levels </span></span></span></p>"
        },
        {
          "id": 79868,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced IRS phosphorylation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a primary defect responsible for insulin resistance in type 2 diabetes?</span></span></p>",
      "unique_key": "Q7377698",
      "question_audio": null,
      "question_video": null,
      "map_id": 19950,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Reduced IRS phosphorylation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all the options can contribute to insulin resistance, the primary defect in type 2 diabetes is a <strong>post-receptor defect,</strong> namely reduced tyrosine phosphorylation of insulin receptor substrates (IRS). This impairment in the intracellular signaling cascade disrupts insulin&#39;s ability to promote glucose uptake and utilization in target tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Reduced Insulin receptor levels:</span></strong><span style=\"font-size:12.0pt\"> Although receptor levels can be reduced in insulin resistance, this is often a secondary effect due to chronic hyperinsulinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Reduced Tyrosine kinase activity:</span></strong><span style=\"font-size:12.0pt\"> This can also be a consequence of chronic hyperinsulinemia rather than the primary cause of insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased insulin levels:</span></strong><span style=\"font-size:12.0pt\"> Increased insulin levels (hyperinsulinemia) are a compensatory response to insulin resistance, not the primary cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced IRS phosphorylation is a primary defect responsible for insulin resistance in type 2 diabetes.</span></span></span></p>",
      "correct_choice_id": 79868,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19977,
      "choices": [
        {
          "id": 79869,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79870,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79871,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus </span></span></span></p>"
        },
        {
          "id": 79872,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old patient presents with the following blood sugar values. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-092501.png\" style=\"height:121px; width:300px\" /></span></span></p>",
      "unique_key": "Q6079472",
      "question_audio": null,
      "question_video": null,
      "map_id": 19951,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Normal glucose tolerance</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s blood glucose values fall within the normal range for all three tests:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FBS (Fasting Blood Sugar):</span></strong><span style=\"font-size:12.0pt\"> 98 mg/dL (normal range: &lt;100 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2-hour PG (2-hour Postprandial Glucose):</span></strong><span style=\"font-size:12.0pt\"> 130 mg/dL (normal range: &lt;140 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HbA1c (Glycated Hemoglobin):</span></strong><span style=\"font-size:12.0pt\"> 5.0% (normal range: &lt;5.7%)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Impaired glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> This would be the diagnosis if the 2-hour PG was between 140-199 mg/dL, but the patient&#39;s value is below this range.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Diabetes Mellitus:</span></strong><span style=\"font-size:12.0pt\"> This diagnosis requires either a fasting blood sugar of &ge;126 mg/dL, a 2-hour PG of &ge;200 mg/dL, or an HbA1c of &ge;6.5%.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. None of the above:</span></strong><span style=\"font-size:12.0pt\"> The correct answer is listed in the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance is indicated by fasting blood sugar &lt;100 mg/dL, 2-hour postprandial glucose &lt;140 mg/dL, and HbA1c &lt;5.7%.</span></span></span></p>",
      "correct_choice_id": 79869,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19978,
      "choices": [
        {
          "id": 79873,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79874,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79875,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus </span></span></span></p>"
        },
        {
          "id": 79876,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old patient came with the following reports. What is the diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-092709.png\" style=\"height:208px; width:400px\" /></span></span></p>",
      "unique_key": "Q6442224",
      "question_audio": null,
      "question_video": null,
      "map_id": 19952,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Impaired glucose tolerance</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s blood glucose values indicate impaired glucose tolerance (IGT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FBS (Fasting Blood Sugar):</span></strong><span style=\"font-size:12.0pt\"> 118 mg/dL falls within the range for prediabetes or impaired fasting glucose (100-125 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2-hour PG (2-hour Postprandial Glucose):</span></strong><span style=\"font-size:12.0pt\"> 160 mg/dL falls in the range for impaired glucose tolerance (140-199 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HbA1c (Glycated Hemoglobin):</span></strong><span style=\"font-size:12.0pt\"> 5.9% falls within the range for prediabetes (5.7-6.4%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGT is a pre-diabetic condition where the body does not process glucose as efficiently as it should, leading to higher-than-normal blood sugar levels after eating. It is a risk factor for developing type 2 diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> All values should be within the normal range for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Diabetes Mellitus:</span></strong><span style=\"font-size:12.0pt\"> To diagnose diabetes, either the FBS needs to be &ge;126 mg/dL, the 2-hour PG needs to be &ge;200 mg/dL, or the HbA1c needs to be &ge;6.5%.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. None of the above:</span></strong><span style=\"font-size:12.0pt\"> The correct answer is listed in the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance is indicated by fasting blood sugar between 100-125 mg/dL, 2-hour postprandial glucose between 140-199 mg/dL, and HbA1c between 5.7-6.4%.</span></span></span></p>",
      "correct_choice_id": 79874,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19981,
      "choices": [
        {
          "id": 79885,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">10%</span></span></span></p>"
        },
        {
          "id": 79886,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">50%</span></span></span></p>"
        },
        {
          "id": 79887,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">85%</span></span></span></p>"
        },
        {
          "id": 79888,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">100%</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">How commonly are islet cell antibodies found in patients with new-onset type 1 diabetes?</span></span></p>",
      "unique_key": "Q1837994",
      "question_audio": null,
      "question_video": null,
      "map_id": 19954,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) 85%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ICAs are present in the majority of individuals (&gt;85%) diagnosed with new-onset type 1 DM,</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Present in minority of individuals with newly diagnosed young type 2 DM (5&ndash;10%), and occasionally in individuals with gestational diabetes mellitus (&lt;5%). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ICAs are present in 3&ndash;4% of first-degree relatives of individuals with type 1 DM. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In combination with impaired insulin secretion after IV glucose tolerance testing, they predict a &gt;50% risk of developing type 1 DM within 5 years. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increasing numbers of autoantibodies are associated with an increased risk of diabetes development. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In children with multiple autoantibodies, ~70% developed type 1 DM after 10 years of follow-up, with 80% developing diabetes after 15-year of follow-up. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Islet cell antibodies are found in approximately 85% of patients with new-onset type 1 diabetes.</span></span></span></p>",
      "correct_choice_id": 79887,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19983,
      "choices": [
        {
          "id": 79893,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She will likely require insulin therapy. </span></span></span></p>"
        },
        {
          "id": 79894,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She will have a progressive decline in glycemic control. </span></span></span></p>"
        },
        {
          "id": 79895,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a high risk of developing microvascular complications. </span></span></span></p>"
        },
        {
          "id": 79896,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Her condition is typically managed with diet and exercise.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old girl with a family history of diabetes presents with mild fasting hyperglycemia. She is not obese and has no autoantibodies. Genetic testing reveals a heterozygous mutation in the glucokinase (GCK) gene. Which of the following statements is true regarding her condition?</span></span></p>",
      "unique_key": "Q6587212",
      "question_audio": null,
      "question_video": null,
      "map_id": 19956,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Her condition is typically managed with diet and exercise.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A heterozygous mutation in the glucokinase (GCK) gene leads to a form of maturity-onset diabetes of the young (MODY) known as MODY 2 or GCK-MODY. This condition is characterized by mild, stable fasting hyperglycemia that is usually present from birth. Individuals with MODY 2 typically do not require medication and have a low risk of developing diabetes-related complications. Lifestyle modifications such as diet and exercise are usually sufficient for managing their condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. She will likely require insulin therapy:</span></strong><span style=\"font-size:12.0pt\"> Insulin therapy is generally not required for individuals with MODY 2.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. She will have a progressive decline in glycemic control:</span></strong><span style=\"font-size:12.0pt\"> Glycemic control in MODY 2 tends to be stable over time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. She has a high risk of developing microvascular complications:</span></strong><span style=\"font-size:12.0pt\"> MODY 2 is associated with a very low risk of microvascular complications like retinopathy, nephropathy, and neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY 2 due to GCK mutation is typically managed with diet and exercise, with low risk for complications.</span></span></span></p>",
      "correct_choice_id": 79896,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19985,
      "choices": [
        {
          "id": 79901,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&alpha; </span></span></span></p>"
        },
        {
          "id": 79902,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&beta; </span></span></span></p>"
        },
        {
          "id": 79903,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NeuroD1 </span></span></span></p>"
        },
        {
          "id": 79904,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PDX1</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following mutations causing diabetes will likely respond to sulfonylureas?</span></span></p>",
      "unique_key": "Q4400112",
      "question_audio": null,
      "question_video": null,
      "map_id": 19958,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) HNF1&alpha;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&alpha; mutations cause MODY 3. Individuals with MODY 3 typically have some degree of residual beta-cell function, meaning their pancreas can still produce insulin, although not as effectively as in people without diabetes. Sulfonylureas work by stimulating the release of insulin from beta cells. Therefore, patients with MODY 3 often respond well to sulfonylureas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with MODY3 tend to have lower urinary threshold for glucose (can have glycosuria even with normal blood glucose). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. HNF1&beta;:</span></strong><span style=\"font-size:12.0pt\"> Mutations in this gene cause MODY 5, which is associated with progressive beta-cell dysfunction and may require insulin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. NeuroD1:</span></strong><span style=\"font-size:12.0pt\"> Mutations in this gene cause a rare form of MODY that typically does not respond to sulfonylureas and may require insulin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PDX1:</span></strong><span style=\"font-size:12.0pt\"> Mutations in this gene cause MODY 4, which is also associated with progressive beta-cell dysfunction and may require insulin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Good response to SU: HNF1&alpha; (MODY 3), HNF4&alpha; (MODY 1), ABCC8, PAX4, KCNJ11.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No response to SU: HNF1&beta; (MODY 4), NeuroD1 (MODY 6), KLF11, CEL.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Response uncertain: PDX1 (MODY 5), INS, BLK.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rx not required: Heterozygous GCK mutations (MODY 2).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&alpha; mutations in MODY respond well to sulfonylureas.</span></span></span></p>",
      "correct_choice_id": 79901,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19986,
      "choices": [
        {
          "id": 79905,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketosis-prone type 2 diabetes </span></span></span></p>"
        },
        {
          "id": 79906,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY (Maturity-Onset Diabetes of the Young) </span></span></span></p>"
        },
        {
          "id": 79907,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lean type 2 diabetes </span></span></span></p>"
        },
        {
          "id": 79908,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Prepubertal type 2 diabetes</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are atypical forms of diabetes except?</span></span></p>",
      "unique_key": "Q9013813",
      "question_audio": null,
      "question_video": null,
      "map_id": 19959,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) MODY (Maturity-Onset Diabetes of the Young)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY (Maturity-Onset Diabetes of the Young) is a monogenic form of diabetes caused by a single gene mutation. While it is less common than type 1 or type 2 diabetes, it is not considered an atypical form of diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ketosis-prone type 2 diabetes:</span></strong><span style=\"font-size:12.0pt\"> This is considered atypical as it combines features of both type 1 and type 2 diabetes, with patients experiencing ketosis despite having insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lean type 2 diabetes:</span></strong><span style=\"font-size:12.0pt\"> This is atypical because type 2 diabetes is usually associated with obesity. 80% of type 2 diabetes patients are obese (elderly patients can be thin)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prepubertal type 2 diabetes:</span></strong><span style=\"font-size:12.0pt\"> This is atypical because type 2 diabetes is typically diagnosed in adults. The increasing prevalence of childhood obesity has led to a rise in prepubertal type 2 diabetes cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY is not considered an atypical form of diabetes.</span></span></span></p>",
      "correct_choice_id": 79906,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19987,
      "choices": [
        {
          "id": 79909,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Time in Range (TIR) &gt; 70% </span></span></span></p>"
        },
        {
          "id": 79910,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coefficient of Variation (CV) &gt; 36% </span></span></span></p>"
        },
        {
          "id": 79911,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Time Above Range (TAR) &lt; 25% </span></span></span></p>"
        },
        {
          "id": 79912,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Time Below Range (TBR) &lt; 4%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are standard Continuous Glucose Monitoring (CGM) targets except?</span></span></span></p>",
      "unique_key": "Q5194387",
      "question_audio": null,
      "question_video": null,
      "map_id": 19960,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Coefficient of Variation (CV) &gt; 36%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coefficient of Variation (CV) is a measure of glucose variability, but the standard target is to maintain CV below 36% (not above), indicating less fluctuation in glucose levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Time in Range (TIR):</span></strong><span style=\"font-size:12.0pt\"> Represents the percentage of time spent within the target glucose range (70-180 mg/dL for most individuals). A higher TIR (&gt; 70%) is desirable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Time Above Range (TAR):</span></strong><span style=\"font-size:12.0pt\"> Represents the percentage of time spent above the target glucose range, indicating hyperglycemia. A lower TAR (&lt; 25%) is desirable.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Time Below Range (TBR):</span></strong><span style=\"font-size:12.0pt\"> Represents the percentage of time spent below the target glucose range, indicating hypoglycemia. A lower TBR (&lt;4%) is desirable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-094945.png\" style=\"height:501px; width:400px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Standard CGM targets include Time in Range &gt;70%, Time Above Range &lt;25%, Time Below Range &lt;4%, and CV &le;36%.</span></span></span></p>",
      "correct_choice_id": 79910,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19990,
      "choices": [
        {
          "id": 79921,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency </span></span></span></p>"
        },
        {
          "id": 79922,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">B12 deficiency </span></span></span></p>"
        },
        {
          "id": 79923,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemolysis </span></span></span></p>"
        },
        {
          "id": 79924,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Splenectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Falsely high HbA1c is seen in all except?</span></span></p>",
      "unique_key": "Q4119670",
      "question_audio": null,
      "question_video": null,
      "map_id": 19963,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Hemolysis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c (glycated hemoglobin) reflects the average blood glucose levels over the past 2-3 months. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Conditions that cause falsely elevated HbA1C:</span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&uarr; RBC life span or &darr; turnover:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><em><u>Fe, B12 or folate deficiency, Asplenia</u></em></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Glycation abnormality:</span></strong><span style=\"font-size:12.0pt\"> Uremia/acidosis</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Assay interference:</span></strong><span style=\"font-size:12.0pt\"> Hyperbilirubinemia, alcoholism</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Conditions that cause falsely low HbA1C:</span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&darr; RBC life span or &uarr; turnover:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><em><u>Hemolysis</u></em>, reticulocytosis, recent blood loss or recent PRBC transfusion, EPO therapy, hypersplenism (splenomegaly), Pregnancy</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Glycation abnormality:</span></strong><span style=\"font-size:12.0pt\"> Vitamin C/E (high dose ingestions)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Assay interference:</span></strong><span style=\"font-size:12.0pt\"> Hypertriglyceridemia</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1C is variable in hemoglobinopathies (but in HbC/ HbS &ndash; usually HbA1C is falsely low)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency:</span></strong><span style=\"font-size:12.0pt\"> Causes falsely high HbA1C (due to &darr; turnover)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. B12 deficiency:</span></strong><span style=\"font-size:12.0pt\"> Causes falsely high HbA1C (due to &darr; turnover)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Splenectomy:</span></strong><span style=\"font-size:12.0pt\"> Causes falsely high HbA1C (due to &uarr; RBC life span)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemolysis causes falsely low HbA1c, while iron and B12 deficiency and splenectomy cause falsely high HbA1c.</span></span></span></p>",
      "correct_choice_id": 79923,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19991,
      "choices": [
        {
          "id": 79925,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycated Hb (HbA1c) </span></span></span></p>"
        },
        {
          "id": 79926,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycated albumin </span></span></span></p>"
        },
        {
          "id": 79927,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fructosamine </span></span></span></p>"
        },
        {
          "id": 79928,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1,5-anhydroglucitol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are markers of short-term glycemic control except?</span></span></p>",
      "unique_key": "Q2828001",
      "question_audio": null,
      "question_video": null,
      "map_id": 19964,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Glycated Hb (HbA1c)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c reflects the average blood glucose levels over the past 2-3 months and is therefore a marker of <strong>long-term</strong> glycemic control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glycated albumin:</span></strong><span style=\"font-size:12.0pt\"> Measures glycated form of albumin weeks and is a marker of short-term glycemic control (over 2 weeks). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fructosamine:</span></strong><span style=\"font-size:12.0pt\"> Measures glycated serum proteins (primarily albumin) and is another marker of short-term glycemic control (over 2 weeks).&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 1,5-anhydroglucitol:</span></strong><span style=\"font-size:12.0pt\"> This is a monosaccharide that decreases with recent hyperglycemic spikes and is considered a marker of short-term glycemic control (1-2 weeks).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c is a marker of long-term glycemic control, while glycated albumin, fructosamine, and 1,5-anhydroglucitol are markers of short-term glycemic control.</span></span></span></p>",
      "correct_choice_id": 79925,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53900,
      "choices": [
        {
          "id": 215073,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colon cancer </span></span></span></p>"
        },
        {
          "id": 215074,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hidradenitis suppurativa</span></span></span></p>"
        },
        {
          "id": 215075,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Knee osteoarthritis </span></span></span></p>"
        },
        {
          "id": 215076,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ovarian cancer</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following health conditions are associated with obesity EXCEPT:</span></span></p>",
      "unique_key": "Q3742233",
      "question_audio": null,
      "question_video": null,
      "map_id": 25495,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Ovarian cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obesity is a major risk factor for several types of cancer, including colon cancer. It is also linked to hidradenitis suppurativa and knee osteoarthritis (due to increased stress on knee joints). However, ovarian cancer is not directly associated with obesity (but there is some association with breast and uterine cancers). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Colon cancer:</span></strong><span style=\"font-size:12.0pt\"> Obesity is a known risk factor for colon cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hidradenitis suppurativa:</span></strong><span style=\"font-size:12.0pt\"> Obesity is a major risk factor for this inflammatory skin condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Knee osteoarthritis:</span></strong><span style=\"font-size:12.0pt\"> Excess weight puts stress on joints, increasing the risk of osteoarthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Health risks in obesity:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Cardiovascular:&nbsp;</span></strong><span style=\"font-size:12.0pt\">HTN, CHF, Cor pulmonale, Varicose veins, Pulmonary embolism, CAD, AF (<u>most common arrhythmia in obese individuals</u>).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Endocrine:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Metabolic syndrome<strong>, </strong>Type 2 diabetes (<u>most common complication of<em> </em>obesity</u>)<strong>, </strong>Dyslipidemia, PCOS</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Musculoskeletal:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Hyperuricemia/gout<strong>, </strong>Immobility<strong>, </strong>OA (knees and hips &ndash; <u>most common<em> </em>rheumatologic complication</u>)<strong>, </strong>Low back pain<strong>, </strong>CTS</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Psychological:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Depression/low self-esteem<strong>, </strong>Body image disturbance<strong>, </strong>Social stigmatization</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Integument:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Striae distensae<strong>, </strong>Stasis pigmentation of legs<strong>, </strong>Lymphedema<strong>, </strong>Cellulitis<strong>, </strong>Intertrigo, carbuncles<strong>, </strong>Acanthosis nigricans<strong>, </strong>Acrochordons (skin tags)<strong>, </strong>Hidradenitis suppurativa</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Respiratory:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Exertional<strong> </strong>Dyspnea (<em><u>most common pulmonary complication</u></em>), OSA, Pickwickian syndrome<strong>,</strong>Asthma</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Gastrointestinal:&nbsp;</span></strong><span style=\"font-size:12.0pt\">GERD (<em><u>most common GI complication</u></em>), NAFLD, Cholelithiasis, Hernias, CRC</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Genitourinary:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Urinary stress incontinence<strong>, </strong>Obesity-related glomerulopathy<strong>, </strong>Hypogonadism (male)<strong>, </strong>Breast and uterine cancer</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pregnancy complications</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Neurologic:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Stroke, Idiopathic intracranial hypertension, Meralgia paresthetica, Dementia</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obesity is associated with increased risks of colon cancer, hidradenitis suppurativa, and knee osteoarthritis but not specifically ovarian cancer.</span></span></span></p>",
      "correct_choice_id": 215076,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53902,
      "choices": [
        {
          "id": 215081,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stimulates POMC neurons </span></span></span></p>"
        },
        {
          "id": 215082,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibits NPY/AGRP neurons </span></span></span></p>"
        },
        {
          "id": 215083,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-inflammatory </span></span></span></p>"
        },
        {
          "id": 215084,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resistance common in obese individuals</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect with regards to Leptin in humans?</span></span></p>",
      "unique_key": "Q7301546",
      "question_audio": null,
      "question_video": null,
      "map_id": 25497,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-inflammatory</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leptin is a hormone produced by adipose tissue that plays a key role in regulating energy balance by decreasing appetite and increasing energy expenditure. However, it is not considered to be anti-inflammatory. In fact, some studies suggest that leptin may even have pro-inflammatory effects in certain contexts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-101508.png\" style=\"height:542px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Stimulates POMC neurons:</span></strong><span style=\"font-size:12.0pt\"> Leptin does stimulate proopiomelanocortin (POMC) neurons in the hypothalamus, which leads to decreased appetite (via &alpha; &amp; &beta; MSH). MSH can stimulate BDNF neurons, which can also result in appetite suppression. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhibits NPY/AGRP neurons:</span></strong><span style=\"font-size:12.0pt\"> Leptin also inhibits neuropeptide Y (NPY) and agouti-related peptide (AGRP) neurons, further contributing to appetite suppression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Resistance common in obese individuals:</span></strong><span style=\"font-size:12.0pt\"> Leptin resistance, where the body becomes less responsive to leptin&#39;s signals, is a common feature of obesity. This can lead to increased appetite and difficulty losing weight.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leptin, which is elevated in obesity, stimulates POMC neurons and inhibits NPY/AGRP neurons but is not anti-inflammatory.</span></span></span></p>",
      "correct_choice_id": 215083,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53905,
      "choices": [
        {
          "id": 215089,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bardet-Biedl syndrome</span></span></span></p>"
        },
        {
          "id": 215090,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Albright&#39;s hereditary osteodystrophy</span></span></span></p>"
        },
        {
          "id": 215091,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alstr&ouml;m syndrome</span></span></span></p>"
        },
        {
          "id": 215092,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old man presents to the clinic with his mother for evaluation of obesity. He has been obese since childhood and has an intellectual disability. He also has short stature and small hands and feet. Testosterone levels are low on laboratory testing. Which of the following is the most likely underlying syndrome?</span></span></p>",
      "unique_key": "Q3976715",
      "question_audio": null,
      "question_video": null,
      "map_id": 25499,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Prader-Willi syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient&#39;s presentation aligns well with the classic features of Prader-Willi syndrome (PWS). It is a genetic disorder characterized by:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Childhood-onset obesity:</span></strong><span style=\"font-size:12.0pt\"> Due to hyperphagia (excessive eating).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Intellectual disability </span></strong><span style=\"font-size:12.0pt\">(Mild to moderate) with almond shaped eyes.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Psychiatric:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Obsession, rage.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Short stature &amp; acromicra (Small hands and feet).</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Hypogonadotropic hypogonadism, micropenis &amp; cryptorchidism.</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bardet-Biedl syndrome:</span></strong><span style=\"font-size:12.0pt\"> Characterized by retinitis pigmentosa, polydactyly, and renal abnormalities, which are not mentioned in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Albright&#39;s hereditary osteodystrophy:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is characterized by short stature &amp; characteristic skeletal abnormalities (brachydactyly). Seen with PHP (type 1) &amp; PPHP. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Alstr&ouml;m syndrome:</span></strong><span style=\"font-size:12.0pt\"> Characterized by retinal (cone-rod) dystrophy &amp; sensorineural hearing loss, which are not mentioned in this patient. Diagnosed by Marshall criteria. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi syndrome is characterized by childhood-onset obesity, intellectual disability, short stature, and hypogonadism.</span></span></span></p>",
      "correct_choice_id": 215092,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53907,
      "choices": [
        {
          "id": 215097,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">MC4R </span></span></span></p>"
        },
        {
          "id": 215098,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">POMC </span></span></span></p>"
        },
        {
          "id": 215099,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">PCSK1 </span></span></span></p>"
        },
        {
          "id": 215100,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LEPR</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common gene contributing to obesity in the general population is:</span></span></p>",
      "unique_key": "Q4374687",
      "question_audio": null,
      "question_video": null,
      "map_id": 25501,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) MC4R</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the melanocortin 4 receptor (MC4R) gene are the most common monogenic cause of obesity in the general population. Pathogenic variants in MC4R are found in up to 5-6% of cases of severe childhood obesity and up to 0.3% of the general population. These mutations disrupt the melanocortin signaling pathway, which plays a crucial role in appetite regulation and energy homeostasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. POMC:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the proopiomelanocortin (POMC) gene are less common than MC4R mutations and are associated with severe early-onset obesity, adrenal insufficiency, and red hair pigmentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PCSK1:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the prohormone convertase 1 (PCSK1) gene are also rare and lead to a complex syndrome with obesity, hypoglycemia, and various endocrine deficiencies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. LEPR:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the leptin receptor (LEPR) gene are rare and result in severe early-onset obesity, hyperphagia, and hypogonadotropic hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MC4R gene mutations are the most common genetic cause of obesity in the general population.</span></span></span></p>",
      "correct_choice_id": 215097,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53908,
      "choices": [
        {
          "id": 215101,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laparoscopic adjustable gastric banding </span></span></span></p>"
        },
        {
          "id": 215102,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roux-en-Y gastric bypass </span></span></span></p>"
        },
        {
          "id": 215103,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sleeve gastrectomy </span></span></span></p>"
        },
        {
          "id": 215104,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intragastric balloon placement</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a BMI of 42 kg/m&sup2; and type 2 diabetes mellitus presents with uncontrolled glycemic levels despite optimal medical management. She has no contraindications to surgery. Which of the following procedures is MOST likely to result in long-term remission of her diabetes?</span></span></p>",
      "unique_key": "Q9078555",
      "question_audio": null,
      "question_video": null,
      "map_id": 25502,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Roux-en-Y gastric bypass</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roux-en-Y gastric bypass (RYGB) has been shown to have the highest rates of long-term remission of type 2 diabetes compared to other bariatric procedures. This is likely due to a combination of factors including restriction, malabsorption, and changes in gut hormones that improve glucose metabolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Laparoscopic adjustable gastric banding (LAGB):</span></strong><span style=\"font-size:12.0pt\"> LAGB is primarily a restrictive procedure and has a lower rate of diabetes remission compared to RYGB.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sleeve gastrectomy:</span></strong><span style=\"font-size:12.0pt\"> While sleeve gastrectomy can also induce diabetes remission, the rates are not as high as RYGB, particularly in the long term.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Intragastric balloon placement:</span></strong><span style=\"font-size:12.0pt\"> This is a temporary, non-surgical option for weight loss and is not as effective as bariatric surgery in achieving long-term diabetes remission.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roux-en-Y gastric bypass is the most effective bariatric procedure for long-term remission of type 2 diabetes.</span></span></span></p>",
      "correct_choice_id": 215102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53910,
      "choices": [
        {
          "id": 215109,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lorcaserin </span></span></span></p>"
        },
        {
          "id": 215110,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide </span></span></span></p>"
        },
        {
          "id": 215111,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
        },
        {
          "id": 215112,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bupropion</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following weight loss drugs has been withdrawn recently due to an increased risk of cancers?</span></span></p>",
      "unique_key": "Q2848731",
      "question_audio": null,
      "question_video": null,
      "map_id": 25504,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Lorcaserin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lorcaserin, sold under the brand name Belviq, was withdrawn from the market in 2020 due to an increased risk of cancer identified in a clinical trial. The U.S. Food and Drug Administration (FDA) requested the manufacturer to voluntarily withdraw the drug after the trial data showed a higher occurrence of various types of cancer in patients taking lorcaserin compared to those taking a placebo.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Setmelanotide:</span></strong><span style=\"font-size:12.0pt\"> This drug is approved for specific genetic causes of obesity and is not associated with an increased risk of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liraglutide:</span></strong><span style=\"font-size:12.0pt\"> This GLP-1 receptor agonist is used for weight management and diabetes treatment and has not been shown to increase cancer risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bupropion:</span></strong><span style=\"font-size:12.0pt\"> This antidepressant is sometimes used off-label for weight loss and is not associated with an increased risk of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lorcaserin was withdrawn from the market due to an increased risk of cancer.</span></span></span></p>",
      "correct_choice_id": 215109,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}